Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
WeybridgeSurreyKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,524
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.10 | 3.60 | -0.04% |
| CAC 40 | 8,142.08 | 77.06 | 0.96% |
| DAX 40 | 25,573.66 | 269.60 | 1.07% |
| Dow JONES (US) | 51,886.95 | 204.31 | 0.40% |
| FTSE 100 | 10,737.18 | 78.05 | 0.73% |
| HKSE | 25,042.71 | 291.93 | 1.18% |
| NASDAQ | 26,951.40 | 428.86 | 1.62% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,821.20 | 82.06 | 0.60% |
| S&P 500 | 7,729.11 | 78.61 | 1.03% |
| S&P/ASX 200 | 8,731.90 | 0.70 | 0.01% |
| SSE Composite Index | 3,949.91 | 38.04 | 0.97% |